Article info
PDFCommentary
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
- Correspondence to:
Stephen B Hanauer
MD, Professor of Medicine and Clinical Pharmacology, and Chief, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Hospital, 5841 S. Maryland Ave., MC 4076, Chicago, Il 60637, USA; shanauer{at}uchicago.edu
Citation
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Publication history
- First published August 14, 2007.
Online issue publication
April 18, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2007 by Gut